ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$285.86
−0.05%Next report
Analyst consensus
- Next report date
- Feb 3, 2027
- EPS estimate
- $3.89
- Revenue estimate
- $18.3B
Latest reported
- Last report date
- Oct 30, 2026
- EPS actual
- $3.82
- EPS estimate
- $3.69
- Revenue actual
- $17.4B
- Revenue estimate
- $17.3B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 11
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +2.5%
- Revenue beats (12Q)
- 11
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $310
- PT range
- $247 – $346
- Analysts
- 19
16 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 30, 2026 | $3.69 | $3.82 | Beat 3.41% | $17.4B |
| Jul 31, 2026 | $3.60 | $3.65 | Beat 1.47% | $17.0B |
| Apr 29, 2026 | $2.59 | $2.65 | Beat 2.44% | $15.0B |
| Feb 4, 2026 | $2.63 | $2.71 | Beat 2.85% | $16.6B |
| Oct 31, 2025 | $1.79 | $1.86 | Beat 3.68% | $15.8B |
| Jul 31, 2025 | $2.87 | $2.97 | Beat 3.41% | $15.4B |
| Apr 25, 2025 | $2.38 | $2.46 | Beat 3.36% | $13.3B |
| Jan 31, 2025 | $2.98 | $2.16 | Miss -27.52% | $15.1B |
| Oct 30, 2024 | $2.92 | $3.00 | Beat 2.74% | $14.5B |
| Jul 25, 2024 | $2.57 | $2.65 | Beat 3.11% | $14.5B |
| Apr 26, 2024 | $2.26 | $2.31 | Beat 2.21% | $12.3B |
| Feb 2, 2024 | $2.76 | $2.79 | Beat 1.09% | $14.3B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 3, 2027